HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA

This article was originally published in The Rose Sheet

Executive Summary

Former Office of Review Management Director Murray Lumpkin, MD, appointed acting deputy commissioner, making him the agency's highest ranking physician. Lumpkin will serve as acting Commissioner Schwetz' principal deputy in the near-term and may be in a position to continue in that role if HHS' selection for the commissioner post, former Center for Veterinary Medicine Director Lester Crawford, PhD, is confirmed (1"The Rose Sheet" Oct. 1, p. 7). Lumpkin, whose "position of record" will be senior associate commissioner for international activities and strategic initiatives, overseeing the Office of International Programs, is credited as one of the principle architects of FDA's faster, more predictable drug review performance during the 1990s

You may also be interested in...



FDA Commish Pick OK With Kennedy, Thompson Says; Bush Nod Awaited

Virginia Tech Center for Food & Nutrition Policy Director Lester Crawford, DVM/PhD, may represent the Bush administration's last chance to nominate an FDA commissioner this year.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
UsernamePublicRestriction

Register

RS009704

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel